Acorda Therapeutics, Inc. (ACOR)
(Delayed Data from NSDQ)
$11.74 USD
+1.16 (10.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.74 USD
+1.16 (10.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $11.74 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Teva (TEVA) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.
Can Humana (HUM) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Humana Inc. (HUM) will release fourth-quarter 2016 results on Feb 8, before the market opens.
Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.
GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) is scheduled to report first-quarter fiscal 2017 results on Feb 7, before the opening bell.
Implied Volatility Surging for Acorda Therapeutics (ACOR) Stock Options
by Zacks Equity Research
Investors in Acorda Therapeutics, Inc. (ACOR) need to pay close attention to the stock based on moves in the options market lately.
Allergan (AGN) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Allergan plc (AGN) will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.
GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma
Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
by Arpita Dutt
The Q4 earnings season has started on a good note with both earnings and revenue growth improving compared to recent quarters.
Kura Oncology Starts Dosing Patients in Phase II CMML Study
by Zacks Equity Research
Kura Oncology (KURA) dosed the first patient in a phase II study on tipifarnib for the treatment of chronic myelomonocytic leukemia.
What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?
by Zacks Equity Research
In December, Clovis received the FDA nod for its first product, Rubraca, which sent its shares soaring.
3 Biotech Stocks to Turn the Tide This Earnings Season
by Zacks Equity Research
The biotech sector has strong fundamentals, and healthy product pipelines.